| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open … YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ... The lancet oncology 15 (2), 213-222, 2014 | 2405 | 2014 |
| EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer ZY Dong, JT Zhang, SY Liu, J Su, C Zhang, Z Xie, Q Zhou, HY Tu, CR Xu, ... Oncoimmunology 6 (11), e1356145, 2017 | 415 | 2017 |
| Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer Q Zhou, XC Zhang, ZH Chen, XL Yin, JJ Yang, CR Xu, HH Yan, HJ Chen, ... Journal of clinical oncology 29 (24), 3316-3321, 2011 | 290 | 2011 |
| Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual … YL Wu, WZ Zhong, LY Li, XT Zhang, L Zhang, CC Zhou, W Liu, B Jiang, ... Journal of Thoracic Oncology 2 (5), 430-439, 2007 | 273 | 2007 |
| Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy YS Li, BY Jiang, JJ Yang, XC Zhang, Z Zhang, JY Ye, WZ Zhong, HY Tu, ... Annals of Oncology 29 (4), 945-952, 2018 | 257 | 2018 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 233 | 2020 |
| Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer JJ Yang, HJ Chen, HH Yan, XC Zhang, Q Zhou, J Su, Z Wang, CR Xu, ... Lung cancer 79 (1), 33-39, 2013 | 224 | 2013 |
| Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors … JJ Yang, XC Zhang, J Su, CR Xu, Q Zhou, HX Tian, Z Xie, HJ Chen, ... Clinical Cancer Research 20 (5), 1383-1392, 2014 | 207 | 2014 |
| A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations JJ Yang, Q Zhou, HH Yan, XC Zhang, HJ Chen, HY Tu, Z Wang, CR Xu, ... British journal of cancer 116 (5), 568-574, 2017 | 196 | 2017 |
| A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer HY Tu, EE Ke, JJ Yang, YL Sun, HH Yan, MY Zheng, XY Bai, Z Wang, ... Lung Cancer 114, 96-102, 2017 | 192 | 2017 |
| Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study Q Zhou, CR Xu, Y Cheng, YP Liu, GY Chen, JW Cui, N Yang, Y Song, ... Cancer cell 39 (9), 1279-1291. e3, 2021 | 172 | 2021 |
| Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma H Sun, SY Liu, JY Zhou, JT Xu, HK Zhang, HH Yan, JJ Huan, PP Dai, ... EBioMedicine 60, 2020 | 143 | 2020 |
| Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer J Jee, ES Lebow, R Yeh, JP Das, A Namakydoust, PK Paik, JE Chaft, ... Nature medicine 28 (11), 2353-2363, 2022 | 102 | 2022 |
| Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells BY Jiang, YS Li, WB Guo, XC Zhang, ZH Chen, J Su, WZ Zhong, XN Yang, ... Clinical Cancer Research 23 (18), 5480-5488, 2017 | 102 | 2017 |
| Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer A Li, J Yang, X Zhang, Z Zhang, J Su, L Gou, Y Bai, Q Zhou, Z Yang, ... Clinical Cancer Research 23 (16), 4929-4937, 2017 | 94 | 2017 |
| Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study HM Wang, CY Zhang, KC Peng, ZX Chen, JW Su, YF Li, WF Li, QY Gao, ... Cell Reports Medicine 4 (2), 2023 | 93 | 2023 |
| A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R EE Ke, Q Zhou, QY Zhang, J Su, ZH Chen, XC Zhang, CR Xu, JJ Yang, ... Journal of Thoracic Oncology 12 (9), 1368-1375, 2017 | 93 | 2017 |
| Symptom and quality of life improvement in LUX-Lung 6: An open-label phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive … SL Geater, CR Xu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, ... Journal of Thoracic Oncology 10 (6), 883-889, 2015 | 69 | 2015 |
| Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated NSCLC MM Zheng, YS Li, HY Tu, BY Jiang, JJ Yang, Q Zhou, CR Xu, XR Yang, ... Journal of Thoracic Oncology 16 (2), 250-258, 2021 | 65 | 2021 |
| EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China C Pi, CR Xu, M Zhang, X Peng, X Wei, X Gao, HH Yan, Q Zhou Thoracic Cancer 9 (7), 814-819, 2018 | 61 | 2018 |
Yi-long WuProfessor of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital在 gdph.org.cn 的电子邮件经过验证
